The study is a two-arm, parallel-comparison, single-blind, randomized controlled trial, and will be offered to Kaiser Permanente members aged 18 - 75 years old who present to the Santa Rosa Diabetes Care Management Center with Type 2 diabetes mellitus. Participants will be randomly assigned to one of two treatment arms. The telemedicine group or the group receiving usual care (the control group). This study hopes to show the usefulness of this telemonitoring technology and more specifically, to assess whether this device improves markers of control of diabetes, glycemic control, and cardiovascular risk factors
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
254
Telemonitoring device was installed in patients' homes
Fructosamine
Change from baseline to 6 weeks in serum fructosamine levels
Time frame: 6 weeks
glycosylated hemoglobin
change from baseline to 6 months in serum HbA1c levels
Time frame: 6 months
blood pressure
goal of systolic \< 130 mmHg and diastolic \< 70 mmHg
Time frame: 6 weeks and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.